Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities

Drott, Jenny; Fomichov, Victoria; Starkhammar, Hans; Börjeson, Sussanne; Kjellgren, Karin; Berterö, Carina

doi:10.1097/ncc.0000000000000674

Cited by 15 publications

(15 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the original 46 patients included in the main study assessing neurotoxicity, 43 patients provided data for the present study (Table ). In total, 817 questionnaire responses (226 SOC, 221 FACT‐G and 370 OANQ) were available for analysis both during and post‐chemotherapy treatment.…”

Section: Resultsmentioning

confidence: 99%

“…Follow‐up assessments were performed at 3, 6, 9 and 12 months after the last concluding OXA treatment. The results from frequency, severity, and impact on daily activities of neurotoxicity are reported separately . A study procedure was established that included instructions for nurses in using the mobile phone‐based system.…”

Section: Methodsmentioning

confidence: 99%

“…The questionnaire is divided into three sections corresponding to the side effect locations: upper extremities, lower extremities, and the face/mouth area. Patients first assessed whether they had the specific side effect, yes or no …”

Section: Methodsmentioning

confidence: 99%

“…In one of our longitudinal studies, we showed that the high prevalence of OXA‐neurotoxic side effects significantly interfered with the patient's daily activities in different ways, both in the short and long terms. The results highlight a need for tailored care for these patients . All patients had neurotoxicity that influenced activities in daily life, and therefore, it is important to investigate psychosocial and health issues deeper in this study.…”

Section: Introductionmentioning

confidence: 93%

See 3 more Smart Citations

Sense of coherence and health‐related quality of life in patients with neurotoxicity after cancer chemotherapy: Assessment from a real‐time mobile phone–based system

et al. 2019

Self Cite

View full text Add to dashboard Cite

Objective: In the present study, we aimed to assess sense of coherence (SOC) andhealth-related quality of life (HRQOL) during and after adjuvant chemotherapy by mobile phone-based reporting in patients with colorectal cancer experiencing neurotoxicity. Methods:In this prospective descriptive cohort study, a mobile phone-based system was used to receive a series of real-time longitudinal patient-reported assessments of SOC (13-item), HRQOL (Functional Assessment of Cancer Therapy-General (FACT-G) 27-item), and neurotoxicity (OANQ 29-item) from 43 patients with colorectal cancer after being treated with chemotherapy including oxaliplatin. Measurements were conducted during the whole treatment period (mean 5 cycles) and up to 12 months after completing chemotherapy. Results:In total, 817 questionnaire responses (226 SOC, 221 FACT-G, 370 OANQ) answered during and after chemotherapy treatment were available for analysis. Even though all patients experienced neurotoxicity during the treatment period, HRQOL was stable over time. Over time, the ratings of physical wellbeing tended to increase, while the subscale of social wellbeing tended to decrease. Overall SOC, including the three components comprehensibility, manageability, and meaningfulness was stable during the entire study period. No internal data was missing due to the mobile phone-based system. Conclusions: All patients had neurotoxicity during the treatment period that seemed to affect the social wellbeing component of HRQOL, but SOC seemed unaffected. Real-time patient-reported assessment using mobile phone technology could be valuable in the clinical setting to provide continuous individualised monitoring to help identify patients who need further evaluation to maintain or improve their psychosocial health. Occupation Type of cancer location, n (%)Colon 38 (88) Rectum 5 (12) Chemotherapy, n (%) FOLFOX 2 6 (14) CAPOX 3 37 (86) Oxaliplatin mg (total dose) mean, (range) 918, (120-1680) 1 Sex distribution in follow-up male/female; 3 months (55 %/45 %), 6 months (50 %/50 %), 9 months (40 %/60 %) and 12 months (46 %/54 %). 2 Fluorouracil + leucovorin + oxaliplatin. 3 Capecitabine + oxaliplatin. 4Dose reduction was applied to all patients at some point, mean 5 OXAtreatments.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 93%

See 2 more Smart Citations

Sense of coherence and health‐related quality of life in patients with neurotoxicity after cancer chemotherapy: Assessment from a real‐time mobile phone–based system

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…5). However, the commonly used chemotherapy drugs such as oxaliplatin and irinotecan have apparent side effects 37,38 . Chiauranib may replace these chemotherapeutic drugs and become the new choice for the treatment of KRAS wild-type CRC.…”

Section: Discussionmentioning

confidence: 99%

Chiaurinib Selectively Inhibits Colorectal Cancer with KRAS Wild-Type by Modulation of ROS through Activating the p53 Signaling Pathway

Yin

Xie²,

Jiang

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC) is one of the top three most deadly cancers despite using chemotherapy based on oxaliplatin or irinotecan combined with targeted therapy. Chiaurinib has recently been identified to be a promising anticancer candidate with impressive efficacy and safety. However, the role and molecular mechanisms of Chiaurinib in the treatment of CRC remain to be elucidated.Methods: Cell proliferation and apoptosis were detected by CCK-8, EDU staining, Colony formation assay, TUNEL staining and flow cytometric analysis. ROS production was confirmed by Mito-SOX and DCF-DA fluorescence. RNA-Seq and GSEA analysis were used to explore the mechanisms of the effect of Chiaurinib in KRAS wild-type CRC cells.Results: Our study shows that Chiaurinib inhibits cell proliferation and induces apoptosis in KRAS wild-type CRC cells in a dose- and time-dependent manner, but not mutation ones. Meanwhile, Chiaurinib increases ROS production in KRAS wild-type CRC cells. Moreover, Chiaurinib selectively suppresses KRAS wild-type CRC cells growth in vivo. Mechanistically, Chiaurinib inhibits KRAS wild-type CRC cells by triggering ROS production via activating the p53 signaling pathway. Further, KRAS mutation CRC cells are resistant to Chiaurinib by increasing Nrf2 to stably elevate the basal antioxidant program and thereby lower intracellular ROS induced by Chiaurinib.Conclusions: Taken together, we reveal that Chiauranib induces p53 upregulation, resulting in ROS accumulation, thus inhibiting cell proliferation and inducing apoptosis in KRAS wild-type CRC cells. Our findings provide the rationale for further clinical evaluation of Chiaurinib as a therapeutic agent in treating KRAS wild-type CRC.

show abstract

Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer

Teng

Cohen

Egger

et al. 2021

Support Care Cancer

View full text Add to dashboard Cite

Oxaliplatin-Induced Neurotoxic Side Effects and Their Impact on Daily Activities

Cited by 15 publications

References 28 publications

Sense of coherence and health‐related quality of life in patients with neurotoxicity after cancer chemotherapy: Assessment from a real‐time mobile phone–based system

Sense of coherence and health‐related quality of life in patients with neurotoxicity after cancer chemotherapy: Assessment from a real‐time mobile phone–based system

Chiaurinib Selectively Inhibits Colorectal Cancer with KRAS Wild-Type by Modulation of ROS through Activating the p53 Signaling Pathway

Systematic review of long-term chemotherapy-induced peripheral neuropathy (CIPN) following adjuvant oxaliplatin for colorectal cancer

Contact Info

Product

Resources

About